FORBES says two recent developments using AI models have been underreported:
- Pharmaceutical development in record time – a new drug went from molecular testing to animal trials in 46 days. Normal timelines involve years, leading to multi-million dollar expenditures before marketplace income. Using AI, the developers explored 30,000 variations and narrowed them down to 6 for in-depth analysis. Forbes says the change also could impact the dynamics between small start-ups and Big Pharma.
- New insights in chemistry – Deep neural networks are presenting a new way of seeing the structure of chemical elements, in experiments done at DeepMind, a UK AI lab owned by Alphabet. It’s an example of AI models creating new ways to see things previously not possible. Forbes says better chemistry could lead to completely new materials.
The findings aren’t about using A.I. for marginal gains, like better ad targeting or for preventative maintenance. We’re talking about upending business models.